Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors — two incretin pathways involved in metabolism. This dual action makes it a key comparison compound in metabolic peptide research.
Studied for: glucose-dependent insulin secretion, dual GIP/GLP-1 receptor signalling, appetite regulation, and energy metabolism in research settings.
Presentation: supplied as a 10mg lyophilised powder vial.
Purity: ≥99% (HPLC verified).
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water prior to use in research.
For research purposes only. Not for human or animal consumption. Not a medicinal product.
Reviews
There are no reviews yet.